Abstract: Methods of treating an oxaliplatin-sensitive cancer are disclosed in which a therapy comprising oxaliplatin is initiated, continued until a predetermined endpoint, stopped, then reintroduced after specific criteria are met. This stop-and-go approach reduces or eliminates the neurotoxicity associated with oxaliplatin administration while at the same increasing one or more of the beneficial effects of oxaliplatin therapy.